Author

Peter Irving

Refining the Journey in the Treatment of IBD with Subcutaneous Infliximab (Celltrion Healthcare) (Complete Session)
Refining the Journey in the Treatment of IBD with Subcutaneous Infliximab (Celltrion Healthcare) (Complete Session)

Peter Irving  et al.

EFFICACY OF OZANIMOD AS AN INDUCTION THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS SUBOPTIMALLY CONTROLLED ON CONVENTIONAL TREATMENTS
EFFICACY OF OZANIMOD AS AN INDUCTION THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS SUBOPTIMALLY CONTROLLED ON CONVENTIONAL TREATMENTS

Peter Irving  et al.

EVALUATION OF OZANIMOD EFFICACY AND SAFETY IN OLDER PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE PHASE 3 TRUE NORTH STUDY
EVALUATION OF OZANIMOD EFFICACY AND SAFETY IN OLDER PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE PHASE 3 TRUE NORTH STUDY

Peter Irving  et al.

EVALUATION OF OZANIMOD EFFICACY AND SAFETY IN OLDER PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE PHASE 3 TRUE NORTH STUDY
EVALUATION OF OZANIMOD EFFICACY AND SAFETY IN OLDER PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE PHASE 3 TRUE NORTH STUDY

Targeting inflammation to improve long-term outcomes in UC (Bristol Myers Squibb)
Targeting inflammation to improve long-term outcomes in UC (Bristol Myers Squibb)

Peter Irving  et al.

Webinar | Positioning Treatments in IBD
Webinar | Positioning Treatments in IBD

Peter Irving  et al.

Targeted oral therapies for the treatment of moderate to severe UC (Bristol Myers Squibb)
Targeted oral therapies for the treatment of moderate to severe UC (Bristol Myers Squibb)

Peter Irving  et al.

Perianal Crohn's disease
Perianal Crohn's disease

Peter Irving  et al.

Untangling the Knots: Exploring the Dynamics of Complex Relationships between Ulcerative Colitis and Clostridioides difficile Infections (Tillotts Pharma AG) (Complete Session)
Untangling the Knots: Exploring the Dynamics of Complex Relationships between Ulcerative Colitis and Clostridioides difficile Infections (Tillotts Pharma AG) (Complete Session)

Peter Irving  et al.

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL
EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

Peter Irving  et al.

JAK INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: RESULTS OF AN INTERNATIONAL SURVEY OF PERCEPTIONS, ATTITUDES, AND CLINICAL PRACTICE
JAK INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: RESULTS OF AN INTERNATIONAL SURVEY OF PERCEPTIONS, ATTITUDES, AND CLINICAL PRACTICE

Peter Irving  et al.

OZANIMOD AS A MAINTENANCE THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH MODERATE VS SEVERE ENDOSCOPIC DISEASE
OZANIMOD AS A MAINTENANCE THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH MODERATE VS SEVERE ENDOSCOPIC DISEASE

Peter Irving  et al.

Modernizing Ulcerative Colitis Treatment with S1P Receptor Modulators (Bristol Myers Squibb) (Complete Session)
Modernizing Ulcerative Colitis Treatment with S1P Receptor Modulators (Bristol Myers Squibb) (Complete Session)

Peter Irving

Bringing light to patient centric goals in UC: the LUCENT results (Eli Lilly and Company) (Complete Session)
Bringing light to patient centric goals in UC: the LUCENT results (Eli Lilly and Company) (Complete Session)

Peter Irving  et al.

BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Peter Irving  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY

Peter Irving  et al.

SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS
SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS

Peter Irving  et al.

DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY–NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY–NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

Peter Irving  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

Peter Irving  et al.

TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Peter Irving  et al.

Item 1 - 20 / 35
1
2